About Accure
About Accure
Our Vision:
At Accure, we believe having confidence in your skin helps empower individuals, fostering self-assurance that radiates from within. Our commitment to transforming lives begins with a deep understanding of the impact acne can have on one’s self-esteem and overall well-being. With this understanding, we’ve pioneered a revolutionary approach to acne treatment that goes beyond the traditional and improves patients’ long-term quality of life, free from the limitations of acne.
Our Commitment:
Accure is committed to developing an innovative, differentiated, and protected product for dermatologists and acne patients worldwide. The Accure Acne Laser Treatment, cleared by the FDA and granted CE Mark approval, allows Accure to create a global and exclusive intellectual property portfolio focused on fighting acne.
Why Accure?
The Accure Acne Laser goes beyond the ordinary, delivering a transformative approach toward clear skin:
Precision Engineering: Accure’s advanced technology, backed by scientific research, precisely targets acne at its source (the overactive sebaceous glands) to maximize efficacy.
Trust the pros, trust Accure: The Accure Acne Laser was designed by dermatologists and is exclusively available in the expert hands of dermatology professionals.
Efficiency, Redefined: Say goodbye to prolonged, ineffective treatments. Accure Acne’s Laser Treatment accelerates the acne-clearing process, providing fast improvement1 and dramatic results.2
Powerful: The Accure Acne Laser System prioritizes skin health. The treatment powerfully targets sebaceous glands (a root cause of acne) while preserving the surrounding healthy skin, ensuring a tolerable experience with minimal to no downtime.
Personalized, Individualized Care: No two skin types are the same, and neither are their acne concerns. The Accure Acne Laser System with its “treat-to-temperature” algorithm offers a personalized approach that is effective across all skin types,3 tailoring treatments to individual needs.
A Brief History
Principal Investigator Team Formed
FDA Provides Pivotal Trial Protocol Guidance
First Clinical Site Launched
IRB-approved Back Acne Trial Initiated
IRB-approved Human Safety Trial Initiated
IRB-approved Back Acne Trial Completed
IRB-approved Face Acne Trial Initiated
First Production Unit Available
CE Mark Granted
FDA
CLEARANCE
for the treatment of mild to severe inflammatory acne vulgaris on the face and body
Investment Opportunities
If you are interested in learning about investment opportunities with Accure, please contact us here.
Christopher Carlton
Chief Executive Officer
Chairman of the Board
Founder
Mr. Carlton has substantial industry, entrepreneurial, and high-growth public-company execution expertise. He has an extensive, demonstrated record of success in launching new products into global medical and aesthetic markets. Most recently serving as Chief Executive Officer of Quanta Aesthetic Lasers USA, LLC, Mr. Carlton was recognized by Aesthetics Everything®, the largest social network in aesthetics, as one of the “Top 10 CEOs and Presidents in 2016.”
Previously, Mr. Carlton was President, NA, for Syneron-Candela, one of the largest companies in the aesthetic energy-based device market. Mr. Carlton has significant commercialization experience, and over the past 25 years, has served as Vice President and Global General Manager – Interventional Oncology at Covidien, LTD; was CEO of NASDAQ-listed SRI Surgical; President of Dräger Medical; and served in positions of progressively greater leadership responsibility over eleven years with GE Marquette Medical Systems.
Mr. Carlton holds a BS in Industrial Engineering (With Honors), a Graduate Diploma in Management, and an MBA. He is a graduate of the GE Management Development Institute-Crotonville, and the Program on Negotiation at Harvard Law School.
Karl Nicholls, ACMA
Chief Financial Officer
Karl Nicholls has over 20 years’ experience in the Medical Device and Biotech Industries, from large global companies, such as Covidien, to early-stage companies, such as Biodesix and Accure Acne. Mr. Nicholls is a qualified accountant with a depth and breadth of experience across the entire P&L, from sales and marketing, manufacturing and distribution, to research and development. Mr. Nicholls has successfully overseen all financial aspects of an innovative, fast-growing technology-based division that recorded double-digit revenue growth for 16 straight quarters; a fivefold expansion of the sales team and significant increases in R&D investment. Mr. Nicholls has sat on several portfolio management teams, technology and product development teams, and global leadership teams.
Mr. Nicholls’s experience in these roles has given him a unique ability to think both tactically and strategically; particularly in following a product from concept to successful commercialization.
Alfred (Al) Intintoli
Chief Technology Officer
Mr. Intintoli has over forty years of professional experience in developing laser, optical, and medical devices. He has a unique combination of research & development, engineering, operations, regulatory, quality, clinical trial oversight, intellectual property, and product commercialization experience that is well suited as Accure transitions into a world-class commercial organization.
Prior to joining Accure, Mr. Intintoli spent eight years leading a team at Trice Medical from an early-stage start-up through to commercialization. During this time, Mr. Intintoli grew their medical device offerings and incorporated products from three acquisitions into the quality and regulatory systems as well as expanded upon their original product offerings. Prior to that experience, Mr. Intintoli held ever-increasing roles in research & development, engineering, clinical trial oversight, and operations at PhotoMedex, Surgical Laser Technologies, Quantronix Corporation, the Kearfott Division of the Singer Company, and the Laboratory of Laser Energetics.
Mr. Intintoli has a B.S. degree in optical engineering (with distinction) from the University of Rochester, Institute of Optics. Mr. Intintoli is a member of the American Society for Laser Medicine and Surgery (ASLMS) and the International Society for Optics and Photonics (SPIE) and holds numerous patents in the fields of neurosurgery, hysteroscopy, arthroscopy, hair regrowth suppression, ultraviolet phototherapy, tissue visualization, and laser delivery.
Vlad Paul-Blanc
Chief Commercial Officer
Vladimir Paul-Blanc has over 20 years’ experience in medical devices, with his core expertise in the energy-based devices categories of dermatology, plastic surgery, and medical aesthetics. He has a diversified background in various leadership roles across key functional areas, including clinical education and development, product development and commercialization, both domestic and international business unit leadership roles, business development, and global executive appointments.
Most recently, Mr. Paul-Blanc served as President and General Manager of Thermi, where he led the post-acquisition integration, stabilization, and ultimate carve-out of the business unit to a strategic partner in the medical aesthetics and regenerative medicine space. Prior to Thermi, Mr. Paul-Blanc served 13 years at Solta Medical in diversified and expanded leadership roles, culminating with his appointment as General Manager.
Mr. Paul-Blanc holds a B.A. in Biology from Brown University. He has presented at numerous scientific meetings around the world and has consulted and advised medical device corporations, financial institutions, and medical societies and organizations.
Rafael "Ray" Sierra, PhD
Senior Product Development Advisor
Dr. Ray Sierra was previously Chief Technology Officer of Cynosure, Inc. Dr. Sierra has authored or co-authored more than 30 refereed publications and conference presentations, and three book chapters. He is also the inventor or co-inventor of over 30 U.S. and international patents related to laser design, the use of lasers in medicine, and the measurement of cholesterol.
As a Senior Scientist starting in 1986 at Candela Corp., Dr. Sierra began his long career designing lasers for medical applications. While at Candela he worked on a number of lasers for the treatment of vascular malformations, biliary stones, glaucoma, endarterectomy, tattoos, and pigmented lesions. In 1991 he became Director of Laser Technology and led all the activities of Candela’s Laser Technology Division, including both the laser development as well as the clinical application of the lasers. From 1995 to 1997 at CeramOptec, Dr. Sierra continued the development of medical lasers and their applications, introducing diode lasers for urology and ophthalmology.
Dr. Sierra joined Cynosure Inc. in 1997 as its Chief Technology Officer. In his more than 20 years with Cynosure he oversaw the development and introduction of numerous lasers, including pulse dye lasers for the treatment of vascular malformations, a line of solid-state alexandrite lasers, Nd:YAG lasers and diode lasers for hair removal, ablative Er:YAG lasers for skin rejuvenation, and short-pulse nanosecond lasers, as well as the first commercial picosecond lasers for the treatment of tattoos, pigmentation, and facial rejuvenation. Additionally, he was involved with the introduction of lasers for the treatment of unwanted fat and body contouring, and invasive as well as non-invasive lasers and laser treatments for liposuction, fat reduction, long-term cellulite improvement, and skin tightening. This broad line of products allowed the company to grow from about $25M annual sales to ~$340M over his tenure.
Dr. Sierra holds a bachelor’s degree from Rensselaer Polytechnic Institute (1971), a master’s degree from the University of R.I. (1973), and a PhD from the University of Texas at Dallas (1978), all in Physics. Following graduation from the University of Texas at Dallas, Dr. Sierra served as a Postdoctoral Fellow at the University of Missouri–Rolla, and from 1980 to 1984 he was a Staff Member at Los Alamos National Lab.
Henrik Hofvander
CTO Emeritus
Mr. Hofvander has an extensive background in hi-tech entrepreneurial companies, including more than 20 years with companies founded on laser-based technologies. Mr. Hofvander is the driving force behind many of the unique technical solutions of the Accure device. He also leads Accure’s integrated clinical and technical development, coordinating with clinical and manufacturing partners, and is responsible for Accure’s IP portfolio.
Mr. Hofvander was formerly the CEO of Zolo Technologies, Inc., a venture-capital-backed startup that successfully commercialized laser systems for telecom, aerospace, and ultra-harsh industrial environments. Prior to Zolo, Mr. Hofvander was the GM of Melles Griot Electro-Optics, a company that develops solid-state laser systems. In his career, Mr. Hofvander has raised in excess of $25M of venture funding.
Mr. Hofvander graduated at the top of his class at the Lund Institute of Technology, Sweden, with a BSc and MSc in EE/CS. He was a Fulbright scholar at Columbia University and holds numerous patents.
Michael Estes PhD
Director of Advanced Concepts
Dr. Estes joined the Accure team in 2018 and has been instrumental in the development of the Accure laser and its foundational technologies, particularly real-time skin temperature monitoring and control. Prior to Accure, he led multidisciplinary engineering teams developing OEM diode laser modules, laser spectroscopic systems, and novel plasmonic devices.
Dr. Estes began his career as an engineering officer in the US Air Force, where he was awarded the Air Force Research and Development award in 1998 for his research on high-speed ultraviolet photodetectors.
As a doctoral student at the University of Colorado, he published a theory of “spatial confinement” of electrons in nano-scale disordered semiconductors. His theory has been cited over 150 times.
Dr. Estes holds 14 US patents and has published numerous peer-reviewed journal and conference articles, generating over 900 citations.
Vaughan Daniels-Hepnar
Director of Clinical Education and Development
Mr. Daniels has worked for over 25 years in health care around the use of energy-based medical devices (LASERS) and Laser physics and optimization in clinical settings. A particular focus has been on the establishment and clinical management of new services in primary and secondary care; clinical research, trials, and studies; the development and execution of training programs; and clinical education and the provision of professional training excellence to CPD / CME standards. Mr. Daniels has been accredited with the Continuing Professional Development Office – CPD Provider status and Provider of Training Excellence coupled with Health Economics and Outcomes, and received a Value-Based Health Care award in 2020.
Mr. Daniels has published many clinical papers including “The use of multi setting lasers under clinical review” ISSN: 2059-0393 – 2016, “Initial Experience with New High Powered 120W Holmium for Vaporization of the Prostate” UNOAJ-04-00119 – 2017, “Men’s Power-Pressure Wave Erectile Regeneration-Therapy: an Early Assessment” UNOAJ-04-00136 – 2017, “Clinical Case Review - First HoLEP using Lumenis. LTD patented MOSES technology at the First center in Iraq using the Lumenis. LTD high-power holmium laser system Pulse 120H with Moses technology” gju_raft1006 – 2020, “The Therapeutic Ladder - A Clinician and a Patient Perspective” JUN-08-0033, 2021, along with other clinical papers.
Mr. Daniels vision is to provide ongoing and relevant clinical education to practitioners, focused on the disease states of acne and the efficacious treatment of the cause of acne by de-naturing the sebaceous gland with the Accure Acne Laser Medical Device treatment paradigm.
Aubrey Eck
Clinical and Software Program Manager
Ms. Eck has over 20 years of professional software engineering and product R&D experience across a diverse collection of industries and technologies, including medical and industrial photonics applications. Her extensive experience in customer-facing consulting roles provides a unique insight into the bridging of user experience and technical implementation.
Thomas G Perito
Senior Operations Manager
Mr. Perito was the COO & Co-Founder of Quanta USA Aesthetic Lasers, LLC, which was the exclusive North American distributor for Quanta System, SpA out of Milan, Italy.
Over the last 20 years, Thomas has held a variety of positions, from Director of Information Technology for one of the largest career management firms in the United States, to Marketing and Electronic Media Manager for a Colorado-based interior design company.
Before his leadership roles in the “technology-focused” arena, Thomas owned his first restaurant at age 23. Growing up with his family owning several restaurants, Thomas learned the art of hospitality-based customer service with experiences and lessons that serve him well to this day.
Ed Barbera
Member of the Board of Directors & Founder
Mr. Barbera has over 35 years of experience in developing, operating, and investing in startup companies. He has extensive experience in fundraising and secured over $55M in private equity for a company he previously founded.
Mr. Barbera has played key leadership roles in acquisitions, capital formation, business development, and the operation of numerous startup companies. Mr. Barbera has consistently built organizations with the solid foundation required to sustain rapid growth. His experience demonstrates a style of leadership that integrates integrity and compliance with success.
Accure Acne, Inc. is Mr. Barbera’s third laser-based startup. In addition to lasers, he has a demonstrated track record of success in diverse industries. Mr. Barbera started his career as a Senior Consultant with Peat | Marwick | Mitchell.
Mr. Barbera served on active duty in the United States Navy from 1972 to 1976. He received his Bachelor of Business Administration degree with a major in accounting from UMass Amherst, became a Certified Public Accountant, and has previously been a member of the National and Colorado Societies of CPAs.
Jeffrey O’Donnell, Sr.
Member of the Board of Directors
Jeffrey O’Donnell, Sr., is currently a Managing Director at O’Donnell Partners, a healthcare consulting firm, and is also currently a Venture Partner at Laidlaw Venture Partners, and Managing Member of Runway Healthcare, an early-stage MedTech Accelerator. Mr. O’Donnell retired as Founder/CEO of Trice Medical. Mr. O’Donnell founded Embrella Cardiovascular, sold to Edwards Lifesciences. Mr. O’Donnell served as President and CEO of PhotoMedex from 1999 to 2009. Prior, Mr. O’Donnell was the President and CEO of Cardiovascular Dynamics, which went public on NASDAQ in June of 1996 and subsequently purchased Radiance Medical Systems and Endologix, which is the surviving entity. Mr. O’Donnell held the position of President and CEO of Kensey Nash Corporation. Additionally, he has held several senior sales and marketing management positions at Boston Scientific Corporation, Guidant Corporation, and with Johnson & Johnson’s Orthopedic Division.
Mr. O’Donnell was named Life Sciences CEO of the Year by PwC and the Greater Philadelphia Emerging Entrepreneur of the Year by Ernst & Young. Mr. O’Donnell is also currently the Chairman of the Board of Directors for AerWave Medical and Waypoint Medical.
Samuel E. Navarro
Member of the Board of Directors
Sam is the managing partner and founder of Gravitas Healthcare, LLC, an advisory firm entirely focused on the emerging medical technology industry, with transactions ranging from mergers and acquisitions, strategic partnerships, and investments with the leading corporate consolidators in the industry.
Prior to founding Gravitas Healthcare, Sam spent over two decades on Wall Street with finance, investment banking, mergers and acquisitions, equity research, and investment management experience in the medical device industry. Sam was Managing Director with Cowen & Co., and led, with a team of senior people, their medical technology investment practice, responsible for building the franchise across all product categories, including M&A / Advisory, financing services, and products. Before joining Cowen & Co., Sam spent over four years at The Galleon Group running the Galleon Healthcare Fund as a Senior Portfolio Manager. While at Galleon, he was responsible for all healthcare investments across all sectors, including pharmaceuticals / biotechnology, medical technology / hospital supplies, and all areas of healthcare services. Prior to Galleon, Sam was Global Head of Healthcare Investment Banking at ING Barings, and prior to that, Senior Medical Technology Analyst and Head of Healthcare Equity Research at UBS. Mr. Navarro also held Senior Medical Technology equity research positions at Furman Selz Inc. and Needham & Company. Sam has also served or serves on the boards of Palette Life Sciences, BioSig Technologies, Strata Skin Sciences, Derma Sciences, Dextera Surgical, MicroTherapeutics, Jomed, Pixelux Entertainment, and others. Sam also serves on the Board of Trustees of Stonehill College.
Sam received his MBA in Finance from The Wharton School at the University of Pennsylvania, a Master of Science in Engineering from Stanford University, and a Bachelor of Science in Engineering from the University of Texas at Austin.
Rox Anderson, MD
Harvard Medical School
Chief Scientific & Medical Officer
Founder
Dr. Anderson is objectively the most influential scientist in the field of energy-based devices used in aesthetics. Dr. Anderson graduated from MIT and then received his medical degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology. After completing his dermatology residency and an NIH research fellowship at Harvard, he joined the faculty, where he is now a Harvard Medical School Professor in Dermatology, Director of the Wellman Center for Photomedicine, and adjunct Professor of Health Sciences and Technology at Massachusetts Institute of Technology (MIT).
Dr. Anderson has contributed significant advancements to the effort to cure acne. This includes significant pre-clinical, clinical, and product development efforts that built upon his initial conceptualization and co-development of the concept of microscopic target-selective laser therapy, now in widespread use for removal of pigmented lesions, tattoos, and hair, along with treatment of port wine stains, birthmarks, vocal cords, kidney stones, glaucoma, heart disease, photodynamic therapy for cancer and acne, and optical diagnostics. His research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions.
Dr. Anderson has been awarded over 60 national and international patents and has co-authored over 425 scientific books and papers. He invented or co-invented fractional laser skin treatments, the confocal laser scanning microscope for human skin imaging, and the development of lasers for lithotripsy, cardiovascular and eye diseases. ResearchGate indicates that his 330 publications have been cited by other researchers greater than 21,800 times. Dr. Anderson is considered the father of the aesthetics industry. Dr. Anderson is a 2020 Inductee to the National Inventor’s Hall of Fame.
Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in medical care. These include the entire industry of laser hair removal. His invention of selective cryolipolysis, which uses cold cycles to preferentially remove adipose tissue, led to the formation of Zeltiq Aesthetics, Inc. (ZLTQ), a global aesthetics company that was acquired by Allergan in 2017 for approximately $2.4 billion in cash.
Dr. Anderson has developed treatments for birthmarks, microvascular and pigmented lesions, and tattoo removal. He has also contributed to treatment for vocal cords, kidney stones, glaucoma, heart disease, photodynamic therapy for cancer and acne, and optical diagnostics. Dr. Anderson's research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions.
In addition to research at the Wellman Center, he practices dermatology at Massachusetts General Hospital and teaches at Harvard and MIT.
Emil Tanghetti, MD
Center For Dermatology and Laser Surgery
Principal Investigator
Dr. Tanghetti has published influential papers on the treatment of acne vulgaris through a variety of methods, including lasers and light-based devices, topicals, and drug therapies. In addition to his academic credentials, Dr. Tanghetti brings the valuable insight of a private practice dermatologist. He received early admission to UCLA School of Medicine after only three years of undergraduate studies. Upon completing his medical studies and a 1-year pathology fellowship, Dr. Tanghetti graduated first in his class at UCLA and received the Dean Warren Medal for Academic Excellence. After finishing residencies in Internal Medicine at Stanford University and Dermatology at Harvard School of Medicine, he completed a Photomedicine fellowship at the Massachusetts General Hospital. Dr. Tanghetti is a board-certified dermatologist and a Fellow in the AAD and ASLMS. His work has been published in journals such as Lasers in Surgery and Medicine, Journal of Dermatologic Surgery, the Journal of Cosmetic and Laser Therapy, and Cutis, and he has presented data at the meetings of the American Society for Laser Medicine and Surgery and the American Academy of Dermatology, as well as Laser Innsbruck. Dr. Tanghetti is an internationally recognized speaker and consultant.
Roy Geronemus, MD
Laser & Skin Surgery Center of New York
Principal Investigator
Dr. Geronemus is Director of the Laser and Skin Surgery Center of New York, is a graduate of Harvard University, the University of Miami School of Medicine, and the New York University Medical Center, where he was the chief resident and fellowship-trained in Mohs Micrographic Surgery and Cutaneous Oncology. He is a Clinical Professor of Dermatology at New York University Medical Center, where he founded its laser program and served nine years as chief of dermatologic and laser surgery. He is past president of the ASDS and ASLMS. Dr. Geronemus is the Chairman of the Board of the New York Stem Cell Foundation. ASLMS awarded Dr. Geronemus the Ellet Drake award for outstanding contributions to laser medicine and the Leon Goldman award for excellence in clinical laser research. ASDS awarded him the Samuel J. Stegman award for distinguished service, and the University of Miami School of Medicine has elected him into their Hall of Fame. He has published over 350 medical articles, chapters and books.
Fernanda Sakamoto, MD, PhD
Harvard Medical School
Principal Investigator
Dr. Sakamoto is the primary author of the pivotal paper that led to the conclusion that Selective Photothermolysis of sebaceous glands was feasible. This study, which utilized the Jefferson National Accelerator superconducting Free Electron Laser, measured Selective Photothermolysis in the spectrum between 200nm to 3000nm. It was found that optical pulses at “…~1720nm, ~100-125 millisecond pulses showed evidence of selective thermal damage to sebaceous glands…Epidermis was undamaged in all samples.” Dr. Sakamoto is co-author of a chapter entitled, “Laser and Light Therapy for Acne Vulgaris,” published in the 2014 textbook “Laser and Light Source Treatments for the Skin,” is author of over 48 medical articles and is Assistant Professor in Dermatology at Harvard Medical School. She is a fellow of the AAD, fellow of the ASLMS, a member of the Société Française de Dermatologie, of the Brazilian Society of Dermatology, of the Brazilian Society of Dermatological Surgery, of the Brazilian Group of Melanoma, and of the International Society of Dermoscopy. Dr. Sakamoto is on the editorial board of Journal of Investigative Dermatology and has served on the ASLMS Education and International Committees.
E. Vic Ross, MD
Scripps Clinic
Principal Investigator
Dr. Ross is the director of the Scripps Clinic (San Diego Laser and Cosmetic Dermatology Center, a frequent lecturer at national and international meetings on cutaneous laser medicine, and a board-certified dermatologist. Dr. Ross was President of ASLMS and elected to the board of the ASDS. Dr. Ross serves on the editorial board of two major dermatologic journals. Dr. Ross graduated summa cum laude with a B.S. in physics from Mississippi State University. He obtained his medical degree from the Tulane University School of Medicine, where he was a junior-year inductee into Alpha Omega Alpha. In 1992, Dr. Ross completed a three-year dermatology residency at the National Naval Medical Center in Bethesda. In 1994 he was the first Navy-sponsored fellow in Photomedicine and Lasers at Massachusetts General Hospital. His special interests are laser skin resurfacing, fractional laser applications, photodynamic therapy, non-ablative skin remodeling, laser treatment of leg veins, laser treatment of acne, and laser hair reduction in dark-skinned patients. He is the author of over 125 articles and seven book chapters.
H. Ray Jalian, MD
Cosmetic Dermatologist Serving Beverly Hills, CA
Principal Investigator
Dr. Ray Jalian, a board-certified dermatologist by the American Board of Dermatology, brings to Accure some impressive credentials. With a Dermatology Fellowship at Harvard/Mass General following his medical training at UCLA and Cedars Sinai, Dr. Jalian has acquired particular skills with fractional laser. His laser specialties include acne scarring, trauma, surgical scars, and photo-damaged skin. Dr. Jalian is the 2020 Honorary Award Recipient of the Dr. Horace Furumoto Young Investigator Award from ASLMS, as well as a 2018 ASLMS Presidential Citation.
Dr. Jalian graduated phi beta kappa from the University of California, Los Angeles, with a Bachelor of Science degree in microbiology, immunology, and molecular genetics. He attended medical school at the David Geffen School of Medicine at UCLA, where he graduated Alpha Omega Alpha.
He served as chief resident at UCLA, followed by a clinical fellowship at the Wellman Center of Photomedicine at Massachusetts General Hospital. Research interests include pathogenesis and treatment of acne and vascular malformations. Dr. Jalian is on the dermatology team at Rebecca Fitzgerald, MD Dermatology in Los Angeles, CA. Prior to joining the practice, he was on staff at UCLA Department of Medicine in Santa Monica, CA.
Christos C. Zouboulis, MD
Brandenburg Medical School Theodor Fontane
Clinical Consultant
Prof. Dr. med. Prof. honoraire Dr. h.c. Christos Zouboulis is Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center and Founding Professor of Dermatology and Venereology at the Theodor Fontane Medical University of Brandenburg, Germany. He currently serves as President of the European Hidradenitis Suppurativa Foundation (EHSF) e.V., Honorary President of the European Society of Preventive, Regenerative and Anti-Aging Medicine (ESAAM) and Board member of the European Academy of Dermatology and Venereology (EADV) and the International Society on Behçet’s Disease. Prof. Zouboulis is currently the Editor of the EADV News, Co-Editor of Rejuvenation Research and serves in the Editorial Boards of several leading international scientific journals. He was elected Prof. honoraire of the University of Franche-Comté, Besançon, France, Dr. h.c. of the National Kapodistria University of Athens and Visiting Professor of the Jiao Tong University of Shanghai, China. He is an honorary member of the French, the Hungarian, the Maltese, and the Lithuanian Dermatological Societies. Prof. Zouboulis has an extensive publication record on skin endocrinology, the pilosebaceous unit and its diseases, skin stem cells, molecular aging, cryosurgery, and rare skin diseases. He has received numerous awards, including the Oskar Gans Prize, the EADV Research Fellowship, the Felix Wankel Animal Protection Research Prize, the Paul Gerson Unna Prize and the Springer Prize for Dermatology. His Departments have been decorated with the title "Germany land of ideas - 2009 place of excellence" for the work on skin stem cells.
James Leyden, MD
Perelman School of Medicine
Clinical Consultant
Dr. James J. Leyden, emeritus professor of Dermatology at the University of Pennsylvania, has been a consultant to the Food and Drug Administration, the Federal Trade Commission, and to drug regulation agencies in England, Germany, and Austria. A past member of the American Academy of Dermatology Board of Directors and former chairman of the Board of the Dermatology Foundation, his research has focused on a variety of clinical problems, including bacterial and fungal infections, acne, aging and photoaging, and developing methodologies for in-vivo evaluation of antimicrobial effects. He has studied mechanisms of inflammation in acne, bacterial taxonomy, and bacterial production of body odors. Dr. Leyden has also been instrumental in developing, testing, and commercializing Retin-A, Accutane, Bactroban, Nizoral, Cleocin, Benzamycin, Benzaclin, and Minocin. He is internationally recognized for his contributions to dermatology, particularly to the understanding of the pathophysiology, diagnosis, and treatment of acne and rosacea.
References:
- In multiple IRB-approved studies, patients showed an average 29% reduction after the first treatment. Data on file, Accure Acne, Inc. Individual results may vary.
- In IRB-approved studies, patients showed an average 70% reduction in acne lesions 6 months after 4 treatments, spaced 1 month apart. Data on file, Accure Acne, Inc. Individual results may vary.
- In multiple IRB-approved trials, patients of all Fitzpatrick skin types were included and treated, with no differences in target temperature or outcomes. Data on file, Accure Acne, Inc. Individual results may vary.